Home > Dermatology > EADV 2019 > Spotlight on Psoriasis > IL-17 blocker: effective and safe in patients with comorbidities

IL-17 blocker: effective and safe in patients with comorbidities

Presented By
Dr Alice Gottlieb, Tufts University School of Medicine, USA
EADV 2019
An analysis of psoriasis patients with comorbidities included in four phase 3 trials showed that secukinumab exhibits a comparable efficacy and safety in patients with comorbidities at baseline [1]. Today, psoriasis is seen as a chronic inflammatory systemic disease. Research has shown that different comorbidities commonly found in patients with psoriasis, such as arthritis, depression, inflammatory bowel disease, and cardiovascular diseases, are directly related to the chronic inflammatory status of psoriasis, and may thus influence efficacy and safety of drug treatment [2]. The IL-17 blocker secukinumab has demonstrated long-lasting efficacy and safety in the complete spectrum of manifestations of psoriatic disease. An analysis of pooled data from four phase 3 trials (i.e. ERASURE, FIXTURE, FEATURE, and JUNCTURE) assessed the incremental burden of comorbidities on clinical efficacy and safety among patients with moderate-to-severe psoriasis.

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on